论文部分内容阅读
目的 研究替吉奥联合吉西他滨治疗转移性胰腺癌的疗效和安全性.方法 选取在我院接受治疗的转移性胰腺癌的患者50例,按治疗方法的不同将其分为联合组和对照组,联合组患者此案有替吉奥联合吉西他滨进行治疗,对照组采用吉西他滨进行治疗,观察两组的治疗效果和不良反应的发生率.结果经治疗后发现,联合组中的治疗有效率为9600%,对照组患者的治疗有效率为8400%,两组比较差异较明显P<005,具有统计学意义.联合组患者不良反应的发生率为400%,对照组中的不良反应的发生率为1200%,,两组比较差异较明显P<005,具有统计学意义.结论 在治疗转移性胰腺癌时采用替吉奥联合吉西他滨进行治疗可以提高患者的治疗有效率,减缓癌症的扩散,而且不良反应的发生率较少,值得临床推广.
Objective To study the efficacy and safety of tegaserod combined with gemcitabine in the treatment of metastatic pancreatic cancer.Methods Fifty patients with metastatic pancreatic cancer who were treated in our hospital were divided into two groups according to different treatment methods: The patients in the combined group were treated with gemcitabine and gemcitabine in the control group and gemcitabine in the control group, and the treatment effect and the incidence of adverse reactions were observed.Results After treatment, the effective rate in the combined group was 9600% , The treatment of patients in the control group was 8400%, the difference between the two groups was significantly P <005, with statistical significance.The incidence of adverse reactions in the combination group was 400%, the incidence of adverse reactions in the control group was 1200 %, The difference between the two groups was more significant P <005, with statistical significance.Conclusion The treatment of metastatic pancreatic cancer with getigat plus gemcitabine can improve the patient’s treatment efficiency, reduce the spread of cancer, and adverse reactions Less incidence, worthy of clinical promotion.